Arising from Parkinson’s disease research, it has been shown that A2A receptor antagonists (e.g., ciforadenant or taminadenant) harbor antitumor activity in cancers associated with high levels of CD39 and CD73 in the tumor microenvironment (TME) (Pinna 2014; Houthuys et al. 2019). The gene discussed is ENTPD1; the disease is neoplasm.